Sitemap

  1. Who We Are
    1. Global Organization
    2. History
    3. Our Leadership Team
      1. Chris Round
      2. Eduardo Fabiano
      3. Betania Glorio
      4. Tim Golden
      5. Libby Horne
      6. Michael MacDougall
      7. Daniel McHugh
      8. Gaby Murphy
      9. Kirk Taylor
      10. Venkat Thiruvallur
      11. Sarah Turner
      12. Dan Van Horn
      13. Emily Vlasak
      14. Lisa Walsh
  2. Vibrant Thoughts
    1. Cycling Inspiration Through the Community
    2. Remembering the Hopes and Dreams of Future Fathers
    3. Clinical Trials Won’t Ever Be the Same & Why That’s a Good Thing
    4. COVID’s Costs on Workplace Equality – How Women Have Overpaid
    5. A Gathering of the Minds to Help Generations to Come
    6. “I’M IN” to Deliver on Diversity for Patients
    7. Small Steps Make a Big Impact: Moving from Conservation to Sustainability
    8. 31 Days to Recognize Bladder Cancer Awareness Month
    9. Top 5 Family-Building Tips for LGBTQ+ Communities
    10. Finding the Value in VBCs
    11. 25+ Years of Commitment… and Still Going Strong for the HIV Community
  3. Contact Us
  4. Partnering
  5. Corporate Responsibility
    1. Embracing Carers
    2. Healthy Women, Healthy Economies
    3. Environmental Commitment
    4. Corporate Giving
    5. Patient Safety
  6. News
    1. Press Releases
      1. 2022-12-22 Mersana ADC Collaboration
      2. 2022-11-21 Research and Development Update
      3. 2022-10-26 New Data for Evobrutinib
      4. 2022-10-26 EMD Serono Showcases Depth of MS Portfolio at ECTRIMS
      5. 2022-09-21 Nerviano Collaboration
      6. 2022-09-07 ESMO 2022 xevinapant Five Year Data
      7. 2022-09-07 EMD Serono to Highlight Data at ESMO 2022
      8. 2022-06-04 EMD Serono advances development programs in oncology
      9. 2022-05-26 ASCO 2022 Highlights
      10. 2022-03-31 Advances in MS Portfolio with Key Efficacy and Safety Data at AAN 2022
      11. 2022-02-24 New MAVENCLAD® Data at ACTRIMS Forum 2022
      12. 2022-02-18 TEPMETKO® for Patients with Advanced NSCLC with METex14 Skipping Alterations
      13. 2022-02-18 BAVENCIO® First-Line Maintenance Treatment of Advanced UC Patients
      14. 2022-02-17 Sustainable Slim Pack for Fertility Medication
      15. 2021-12-17 TEPMETKO receives positive CHMP opinion
      16. 2021-11-29 EMD Serono Launches New Fertility LifeLines™ Portal
      17. 2021-11-17 New Data Show Dramatic Emotional Toll of Pandemic on Unpaid Caregivers of Peopl
      18. 2021-10-14 New Data Presented at ECTRIMS Show Evobrutinib
      19. 2021-10-13 New Real-World MAVENCLAD® Data
      20. 2021-10-04 EMD Serono Completes Enrollment of Evobrutinib ECTRIMS 2021
      21. 2021-09-13 ESMO WCLC 2021 Highlights
      22. 2021-05-19 ASCO21 Data
      23. 2021-04-23 New Data for MAVENCLAD® Use During the COVID-19 Pandemic
      24. 2021-04-16 Evobrutinib is the First and Only BTK Inhibitor
      25. 2021-04-12 EMD Serono Advances ATR Inhibitor Berzosertib in Small Cell Lung Cancer
      26. 2021-03-16 Topline Data for Bintrafusp Alfa as Second-Line Monotherapy Treatment in Biliary Tract Cancer
      27. 2021-03-01 Licensing Agreement with Debiopharm for Pivotal-Stage Xevinapant
      28. 2021-02-25 New Data Presented at ACTRIMS Forum 2021 Indicate MAVENCLAD®-treated RMS Patients
      29. 2021-02-09 Real-World Evidence Study at Miami CFAR Suggests HIV-Associated Wasting Remains an Underappreciated Comorbidity
      30. 2021-02-04 Merck KGaA, Darmstadt, Germany, Announces Leadership Change for North America and Global Innovative Medicine Franchises in Healthcare
      31. 2021-02-03 FDA Approves TEPMETKO® as the First and Only Once-daily Oral MET Inhibitor for Patients with Metastatic NSCLC with METex14 Skipping Alterations
      32. 2021-01-25 European Commission Approves BAVENCIO® (avelumab) for First-Line Maintenance Treatment
      33. 2021-01-20 Merck KGaA, Darmstadt, Germany Announces Update on the INTR@PID Clinical Program Including Lung 037 Study
      34. 2020-12-11 BAVENCIO® (avelumab) Receives Positive CHMP Opinion
      35. 2020-11-18 EMD Serono's Embracing Carers™ Announces Study Results on COVID-19 and Caregive
      36. 2020-10-15 EMD Serono Announces Retirement of Dr. Luciano Rossetti
      37. 2020-09-18 BAVENCIO Pivotal Phase III JAVELIN Bladder 100 Results Published
      38. 2020-09-13 ESMO 2020 - Oncology Portfolio and Pipeline with Data in Multiple Cancers
      39. 2020-09-11 Merck KGaA - Positive Phase II Results for Investigational Sonelokinab (M1095)
      40. 2020-09-03 EMD Serono - New Data at ACTRIMS-ECTRIMS MSVirtual2020 Meeting
      41. 2020-08-25 FDA Accepts Filing of New Drug Application for Tepotinib
      42. 2020-08-05 EMD Serono statement on Rebif® (interferon beta-1a) for the ACTT 3 trial
      43. 2020-06-30 FDA Approves BAVENCIO as First-Line Maintenance Treatment
      44. 2020-06-25 First Clinical Trial of TLR7 and 8 Inhibitor as a Potential Treatment for Sever
      45. 2020-06-08 EMD Serono Announces Launch of MS in the 21st Century Website
      46. 2020-05-29 New England Journal of Medicine: Primary Analysis of VISION Data for Tepotinib
      47. 2020-05-28 Merck KGaAand Twitch Join Forces on World Multiple Sclerosis Day
      48. 2020-05-27 Rebif® U.S. Label Now Includes Pregnancy Outcomes and Lactation Information
      49. 2020-05-23 Evobrutinib First BTK Inhibitor to Report Efficacy+Safety in MS Over 108 Weeks
      50. 2020-05-13 Breakthrough Innovation in Cancer Care to Be Presented at ASCO 2020
      51. 2022-04-30 EMD Serono - ASCO 2020 to Showcase Significant Clinical Advances in Cancer Care
      52. 2020-04-09 EMD Serono and Pfizer Receive US FDA Breakthrough Therapy Designation and Submit Application for BAVENCIO®
      53. 2020-03-25 TEPMETKO® (Tepotinib) Approved in Japan for Advanced NSCLC with METex14 Skipping Alterations
      54. 2020-03-19 Combating the Spread of COVID-19
      55. 2020-03-18 2020-03-18 Merck KGaA statement updates for the INTR@PID Lung 037 study
      56. 2020-03-13 EMD Serono and Pfizer Provide Update on Phase III JAVELIN Head and Neck 100 Study
      57. 2020-01-09 EMD Serono and MyHealthTeams Launch Family Planning Resource Center to Provide Families Affected by Multiple Sclerosis
      58. 2020-01-06 BAVENCIO Improved Overall Survival in Patients With Urothelial Carcinoma
    2. Download Gallery
      1. Sites & Buildings
        1. EMD Serono Headquarters, Rockland, MA - Exterior
        2. EMD Serono R&D Institute, Billerica, MA - Company Logo on Building
        3. EMD Serono R&D Institute, Billerica, MA - Aerial View
        4. EMD Serono R&D Institute, Billerica, MA - Cafeteria Booths
        5. EMD Serono R&D Institute, Billerica, MA - Cafeteria
        6. EMD Serono R&D Institute, Billerica, MA - Laboratory
        7. EMD Serono R&D Institute, Billerica, MA - Sculpture
      2. Logos
        1. EMD Serono Logo Red
        2. EMD Serono Logo Cyan
        3. EMD Serono Logo Yellow
      3. b-roll
        1. EMD Serono R&D Institute, Billerica, MA - B-Roll
        2. EMD Serono Headquarters, Rockland, MA - B-Roll
    3. Press Release Archive